Phase III study of tocilizumab added to remdesivir in patients with severe Covid-19 pneumonia fails to meet primary endpoint

The REMDACTA study, which evaluated the addition of tocilizumab to remdesivir, did not meet its primary endpoint of improved time to hospital discharge, or any of its key secondary endpoints (likelihood of death, progression to mechanical ventilation or death, clinical status).

Roche